<SEC-DOCUMENT>0001415889-25-021779.txt : 20250814
<SEC-HEADER>0001415889-25-021779.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814130412
ACCESSION NUMBER:		0001415889-25-021779
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88266
		FILM NUMBER:		251216700

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Frazier Life Sciences Public Fund, L.P.
		CENTRAL INDEX KEY:			0001863769
		ORGANIZATION NAME:           	
		EIN:				862999645
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		650-325-5156

	MAIL ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
		<previousAccessionNumber>0001193125-24-029534</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001863769</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>1</amendmentNo>
	      <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>08/12/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001501756</issuerCik>        <issuerName>ADVERUM BIOTECHNOLOGIES, INC.</issuerName>        <issuerCusip>00773U207</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>100 CARDINAL WAY</com:street1>
                    <com:city>REDWOOD CITY</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94063</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	   				        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
		      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1129057.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1129057.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1129057.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.4</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.P. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1129057.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1129057.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1129057.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.4</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1129057.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1129057.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1129057.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.4</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences Public Overage Fund, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>427500.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>427500.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>427500.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP Overage, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>427500.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>427500.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>427500.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP Overage, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>427500.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>427500.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>427500.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.0</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>129870.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>129870.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>129870.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.6</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>129870.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>129870.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>129870.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.6</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>129870.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>129870.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>129870.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.6</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>272945.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>272945.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>272945.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.3</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>272945.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>272945.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>272945.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.3</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>272945.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>272945.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>272945.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.3</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences XII, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>118059.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>118059.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>118059.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.6</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XII, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>118059.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>118059.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>118059.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.6</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XII, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>118059.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>118059.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>118059.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.6</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The reported securities represent shares of Common Stock held by the Reporting Person as of the date of this filing and do not include any warrants held by the Reporting Person. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>James N. Topper</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>129870.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>129870.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>129870.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.6</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The reported securities represent shares of Common Stock held by the Frazier Life Sciences X, L.P as of the date of this filing and do not include any warrants held by the Frazier Life Sciences X, L.P. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Patrick J. Heron</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>129870.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>129870.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>129870.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.6</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The reported securities represent shares of Common Stock held by the Frazier Life Sciences X, L.P as of the date of this filing and do not include any warrants held by the Frazier Life Sciences X, L.P. See Item 4(a) to this Schedule 13G.

The percentage listed in row 11 is calculated based on 20,984,161 shares of Common Stock outstanding on August 5, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Albert Cha </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>0.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>James Brush</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>0.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Daniel Estes</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>0.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>ADVERUM BIOTECHNOLOGIES, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>100 CARDINAL WAY, REDWOOD CITY, CA, 94063.</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>The entities and persons filing this statement (collectively, the "Reporting Persons") are:

Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P.
FHMLSP, L.L.C.
Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF")
FHMLSP Overage, L.P.
FHMLSP Overage, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P.  ("FLS XII")
FHMLS XII, L.P.
FHMLS XII, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron")
Albert Cha
James Brush
Daniel Estes
</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>The address of the principal place of business for each of the Reporting Persons is:

c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite B
Palo Alto, CA 94304
</principalBusinessOfficeOrResidenceAddress>        <citizenship>The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.</citizenship>      </item2>

        <item3>
		        <notApplicableFlag>Y</notApplicableFlag>

      </item3>



    <item4>
    <amountBeneficiallyOwned>The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

FLSPF directly holds 1,129,057 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Schedule 13G corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior filings.

FLSPOF directly holds 427,500 shares of Common Stock. FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Schedule 13G corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior filings.

FLS X directly holds 129,870 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X.

FLS XI directly holds 272,945 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Schedule 13G corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior filings.

FLS XII directly holds 118,059 shares of Common Stock. FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII, and this Schedule 13G corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior filings.

The above referenced beneficial ownership and amounts reflected on the cover pages hereto do not include certain prefunded warrants to acquire shares of Common Stock (the "Warrants"), the exercise of which is subject to certain beneficial ownership limitations. In this regard, (i) FLSPF holds Warrants to purchase 2,109,948 shares of Common Stock, (ii) FLSPOF holds Warrants to purchase 622,444 shares of Common Stock, (iii) FLS X holds Warrants to purchase 87,094 shares of Common Stock, (iv) FLS XI holds Warrants to purchase 231,904 shares of Common Stock and (v) FLS XII holds Warrants to purchase 404,709 shares of Common Stock, each of which cannot be exercised, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder of such Warrant (together with its affiliates or any other persons acting as a group together with such holder) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

Except as specifically stated herein, the filing of this Schedule 13G shall not be construed as an admission that any Reporting Person is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13G or a member of a "group" with any other person.
</amountBeneficiallyOwned>    <classPercent>The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>
	          <notApplicableFlag>Y</notApplicableFlag>


    </item5>


        <item6>
	  	  <notApplicableFlag>Y</notApplicableFlag>
		        </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>

      </item10>
    </items>

		<exhibitInfo>Exhibit 99.1 Joint Filing Agreement</exhibitInfo>

	    <signatureInformation>
      <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C. </title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences Public Overage Fund, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP Overage, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP Overage, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C. </title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C. </title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences XII, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Gordon Empey</signature>
        <title>By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XII, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Gordon Empey</signature>
        <title>By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XII, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Gordon Empey</signature>
        <title>By Gordon Empey, General Counsel of FHMLS XII, L.L.C.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>James N. Topper</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Patrick J. Heron</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Albert Cha </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>James Brush</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Daniel Estes</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>



  </formData>


    </edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99-08142025_050814.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex-99-08142025_050814.htm</title></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin:0px" align="center"><br></p>
<p style="margin:0px" align="right"><b>EXHIBIT 99.1</b></p>
<p style="margin:0px" align="right"><br></p>
<p style="margin:0px" align="center"><b>JOINT FILING AGREEMENT</b></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; text-indent:48px" align="justify">Pursuant to Rule&nbsp;13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule&nbsp;13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Adverum Biotechnologies, Inc.</p>
<p style="margin:0px; text-indent:48px" align="justify">&nbsp;</p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLSP, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; padding-left:336px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP Overage, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLSP Overage, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px; font-family:Times New Roman Bold,Times New Roman" align="justify"><b>FHMLSP OVERAGE, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By FHMLSP Overage, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP OVERAGE, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br><br></p>
<hr style="margin-bottom: 9.6px; padding-top: 9.6px;" noshade size="1"><p style="page-break-before:always;margin-top:0;margin-bottom:-4pt;font-size:4pt"></p><p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES X, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS X, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS X, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS X, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS X, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS X, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES XI, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XI, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS XI, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XI, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XI, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XI, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES XII, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XII, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS XII, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Gordon Empey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Gordon Empey, General Counsel</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XII, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XII, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Gordon Empey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Gordon Empey, General Counsel</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XII, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Gordon Empey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Gordon Empey, General Counsel</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>*</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">James N. Topper</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>*</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Patrick J. Heron</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>**</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Albert Cha</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>**</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">James Brush</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>***</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Daniel Estes</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;August 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Steve R. Bailey, as Attorney-in-Fact</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify">*<b style="font-family:TimesNewRomanPSMT,Times New Roman; font-size:12pt;font-weight:normal;"> </b>This Joint Filing Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify">**This Joint Filing Agreement was executed by Steve&nbsp;R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify">***This Joint Filing Agreement was executed by Steve&nbsp;R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
